Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (DE:1VT)
FRANKFURT:1VT
1VT Analyst Ratings
Strong Buy
14 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
1VT Stock 12 Month Forecast
Average Price Target
€78.33
▲(297.21% Upside)
| Highest Price Target€109.92 | Average Price Target€78.33 | Lowest Price Target€26.38 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
04/17/25
Leerink Partners
Reiterated
04/14/25
BTIG
Reiterated
04/14/25
Morgan Stanley
Reiterated
04/14/25
Goldman Sachs
Initiated
04/08/25
William Blair
Reiterated
03/26/25
Truist Financial
Reiterated
03/12/25
J.P. Morgan
Reiterated
03/11/25
Jefferies
Reiterated
03/11/25
B.Riley Financial
Reiterated
03/11/25
Citi
€33.56
Hold
70.17%
Upside
Reiterated
02/24/25
Citi Reaffirms Their Hold Rating on Viking Therapeutics (VKTX)We are maintaining our Neutral rating and $38 price target on VKTX.
Scotiabank
€90.07
Buy
356.76%
Upside
Initiated
02/12/25
Viking Therapeutics initiated with an Outperform at ScotiabankViking Therapeutics initiated with an Outperform at Scotiabank
Maxim Group
€105.97→€61.82
Buy
213.46%
Upside
Reiterated
02/07/25
Viking Therapeutic (VKTX) PT Lowered to $70 at Maxim GroupMaxim Group analyst Naz Rahman lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $70.00 (from $120.00) while maintaining a Buy rating.
Raymond James
€107.74→€110.38
Buy
459.76%
Upside
Reiterated
02/06/25
Viking Therapeutics price target raised to $125 from $122 at Raymond JamesViking Therapeutics price target raised to $125 from $122 at Raymond James
Stifel Nicolaus
€83.89
Buy
325.42%
Upside
Reiterated
02/06/25
Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
04/17/25
Leerink Partners
Reiterated
04/14/25
BTIG
Reiterated
04/14/25
Morgan Stanley
Reiterated
04/14/25
Goldman Sachs
Initiated
04/08/25
William Blair
Reiterated
03/26/25
Truist Financial
Reiterated
03/12/25
J.P. Morgan
Reiterated
03/11/25
Jefferies
Reiterated
03/11/25
B.Riley Financial
Reiterated
03/11/25
Citi
€33.56
Hold
70.17%
Upside
Reiterated
02/24/25
Citi Reaffirms Their Hold Rating on Viking Therapeutics (VKTX)We are maintaining our Neutral rating and $38 price target on VKTX.
Scotiabank
€90.07
Buy
356.76%
Upside
Initiated
02/12/25
Viking Therapeutics initiated with an Outperform at ScotiabankViking Therapeutics initiated with an Outperform at Scotiabank
Maxim Group
€105.97→€61.82
Buy
213.46%
Upside
Reiterated
02/07/25
Viking Therapeutic (VKTX) PT Lowered to $70 at Maxim GroupMaxim Group analyst Naz Rahman lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $70.00 (from $120.00) while maintaining a Buy rating.
Raymond James
€107.74→€110.38
Buy
459.76%
Upside
Reiterated
02/06/25
Viking Therapeutics price target raised to $125 from $122 at Raymond JamesViking Therapeutics price target raised to $125 from $122 at Raymond James
Stifel Nicolaus
€83.89
Buy
325.42%
Upside
Reiterated
02/06/25
Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus
Best Analysts Covering Viking Therapeutics
Which Analyst Should I Follow If I Want to Buy DE:1VT and Sell After:
1 Month
xxx
Success Rate
13/22 ratings generated profit
Average Return
+13.47%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +13.47% per trade.
3 Months
xxx
Success Rate
12/22 ratings generated profit
Average Return
+34.80%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +34.80% per trade.
1 Year
Success Rate
12/19 ratings generated profit
Average Return
+164.51%
reiterated a buy rating 2 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +164.51% per trade.
2 Years
xxx
Success Rate
11/19 ratings generated profit
Average Return
+237.23%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.89% of your transactions generating a profit, with an average return of +237.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
1VT Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
24
24
24
30
24
Buy
12
5
4
7
7
Hold
0
0
2
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
29
30
39
34
Each month's total comprises the sum of three months' worth of ratings.
1VT Financial Forecast
1VT Stock Forecast FAQ
What is DE:1VT’s average 12-month price target, according to analysts?
Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 78.33.
What is DE:1VT’s upside potential, based on the analysts’ average price target?
Viking Therapeutics has 297.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Viking Therapeutics a Buy, Sell or Hold?
Viking Therapeutics has a consensus rating of Strong Buy, which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.
What is Viking Therapeutics’s share price target?
The average share price target for Viking Therapeutics is 78.33. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €109.92 ,and the lowest forecast is €26.38. The average share price target represents 297.21% Increase from the current price of €19.72.
The highest analyst share price target is €109.92 ,and the lowest forecast is €26.38. The average share price target represents 297.21% Increase from the current price of €19.72.
What do analysts say about Viking Therapeutics?
Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of Viking Therapeutics?
To buy shares of DE:1VT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.